United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
United Therapeutics Corporation (UTHR) Chairperson & CEO Martine A. Rothblatt reported that stock options held in a family trust were exercised for 9,500 common shares at an exercise price of $117.76 per share on September 29, 2026; 9,500 trust-held common shares were sold that day in multiple transactions.
The exercise and sales were pursuant to a pre-arranged 10b5-1 trading plan Rothblatt adopted on November 7, 2025. The plan will continue until the earlier of exercise of 1,734,410 stock options, all of which expire on March 15, 2027, or December 31, 2026.
A family trust in which United Therapeutics Chairperson & CEO Martine A. Rothblatt shares investment power exercised 9,500 stock options on September 28, 2026, at an exercise price of $117.76 per share, then sold the resulting 9,500 common shares in 14 transactions. Reported weighted-average sale prices ranged from $472.4274 to $486.0050 per share. The exercise and sales were made under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025.
United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt reported that a family trust in which she shares investment power exercised 9,500 stock options on September 25, 2026, at $117.76 per share and received 9,500 common shares. The trust sold those shares that day in multiple transactions: 40 shares at $470.5565; 200 at $471.8378; 800 at $472.8860; 543 at $474.1472; 1,613 at $475.2775; 2,744 at $476.1324; 1,280 at $477.1915; 1,648 at $478.1807; and 632 at $478.9522 per share. Each reported sale price is a weighted average. The exercise and sales were made under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025.
A family trust associated with United Therapeutics Corp. Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options on September 24, 2026, at an exercise price of $117.76, followed by sales of the resulting 9,500 common shares. Reported sale prices ranged from $469.7352 to $480.3300 per share. The exercise and sales were made under a pre-arranged Rule 10b5-1 plan adopted November 7, 2025. The reported option position following the exercise was 366,410 options.
Martine A. Rothblatt, United Therapeutics Corp.'s Chairperson & CEO, reported that family trusts in which she shares investment power exercised 9,500 stock options on September 23, 2026, at an exercise price of $117.76 per share, then sold 9,500 resulting common shares. The reported stock-option position following the exercise was 375,910.
The exercise and sales were made under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025. The plan will continue until the earlier of exercise of 1,734,410 stock options, all expiring March 15, 2027, or December 31, 2026.
A family trust in which United Therapeutics (UTHR) Chairperson & CEO Martine Rothblatt shares investment power exercised options for 9,500 common shares at an exercise price of $117.7600 on September 22, 2026; the reported option position afterward was 385,410. The resulting shares were sold through family trusts in ten transactions that day: 240 at $489.6121, 424 at $490.5378, 736 at $491.4469, 628 at $492.6678, 1,645 at $493.7018, 1,337 at $494.6585, 1,488 at $495.7662, 1,484 at $496.8295, 1,358 at $497.7257 and 160 at $499.0681 per share. Each reported sale price was a weighted average. The exercise and sales were pursuant to a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025.
UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine Rothblatt, through family trusts, exercised stock options for 9,500 shares of common stock at an exercise price of $117.76 per share on September 21, 2026, and sold all 9,500 resulting shares at weighted-average prices between about $492.97 and $496.62 per share. The option exercise and related sales were made pursuant to a Rule 10b5-1 trading plan adopted on November 7, 2025, and the trusts continued to hold 394,910 stock options after the transaction.
UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options on September 18, 2026 at an exercise price of $117.76 per share, receiving 9,500 shares of common stock. On the same date, those 9,500 shares were sold in multiple open-market transactions at weighted average prices generally between the $492–$498 range. Following the option exercise, family trusts associated with Rothblatt held 404,410 stock options, and she also held 40,513 common shares directly and 166 shares indirectly through her spouse. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.
UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options for common stock of UNITED THERAPEUTICS at an exercise price of $117.76 per share on September 17, 2026, and the resulting 9,500 common shares were sold in a series of trades between roughly $492.71 and $501.70 per share. Following the option exercise, the reporting person's family trust held 413,910 stock options that expire on March 15, 2027. The option exercise and related sales were made under a Rule 10b5-1 trading plan adopted on November 7, 2025, which remains in effect until the earlier of the exercise of 1,734,410 options expiring March 15, 2027, or December 31, 2026.
UNITED THERAPEUTICS Corp (UTHR) reported that executive vice president and general counsel Paul A. Mahon exercised employee stock options and sold the resulting shares on September 17, 2026. He exercised 8,300 stock options$146.03
On the same date, he sold 8,300 shares$496–$50247,540 stock optionsRule 10b5-1 trading plan